首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Mutation Rate and Evolution of Fluoroquinolone Resistance in Escherichia coli Isolates from Patients with Urinary Tract Infections
【2h】

Mutation Rate and Evolution of Fluoroquinolone Resistance in Escherichia coli Isolates from Patients with Urinary Tract Infections

机译:尿路感染患者大肠杆菌中的突变率和氟喹诺酮耐药性的演变

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Escherichia coli strains from patients with uncomplicated urinary tract infections were examined by DNA sequencing for fluoroquinolone resistance-associated mutations in six genes: gyrA, gyrB, parC, parE, marOR, and acrR. The 54 strains analyzed had a susceptibility range distributed across 15 dilutions of the fluoroquinolone MICs. There was a correlation between the fluoroquinolone MIC and the number of resistance mutations that a strain carried, with resistant strains having mutations in two to five of these genes. Most resistant strains carried two mutations in gyrA and one mutation in parC. In addition, many resistant strains had mutations in parE, marOR, and/or acrR. No (resistance) mutation was found in gyrB. Thus, the evolution of fluoroquinolone resistance involves the accumulation of multiple mutations in several genes. The spontaneous mutation rate in these clinical strains varied by 2 orders of magnitude. A high mutation rate correlated strongly with a clinical resistance phenotype. This correlation suggests that an increased general mutation rate may play a significant role in the development of high-level resistance to fluoroquinolones by increasing the rate of accumulation of rare new mutations.
机译:通过DNA测序检查了六个基因:gyrA,gyrB,parC,parE,marOR和acrR中氟喹诺酮耐药相关突变的DNA序列,检查了未合并尿路感染患者的大肠杆菌菌株。分析的54个菌株的敏感性范围分布在氟喹诺酮MIC的15种稀释液中。氟喹诺酮类MIC和菌株携带的抗性突变数之间存在相关性,其中抗性菌株在这些基因中有二到五个具有突变。大多数耐药菌株在gyrA中携带两个突变,在parC中携带一个突变。另外,许多抗性菌株在parE,marOR和/或acrR中具有突变。在gyrB中未发现(抗性)突变。因此,氟喹诺酮耐药性的进化涉及几个基因中多个突变的积累。这些临床菌株的自发突变率相差两个数量级。高突变率与临床耐药表型密切相关。这种相关性表明,增加的一般突变率可能通过增加罕见新突变的积累速率,在对氟喹诺酮类药物产生高水平耐药性方面发挥重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号